

WHO GLOBAL AMR/USE SURVEILLANCE SYSTEM (GLASS)

Dr.Laetitia Gahimbare, WHO AFRO/AMR TEAM

**Training Seminar (Webinar) for OIE National Focal Points for
Veterinary Products (Africa, English, Cycle VII)**

23-24 Feb. 2021

Background: WHO Global AMR Surveillance System

- GLASS addresses Strategic Objective 2 of the Global Action Plan on AMR: **Strengthen knowledge and evidence base through surveillance and research.**
- WHO Global AMR Surveillance System (GLASS)
 - provides a standardized approach to the collection, analysis, and sharing of AMR data by countries, and enables the documentation of the status of existing or newly developed AMR surveillance systems;
 - promotes a shift from surveillance approaches based solely on laboratory data to a system that includes epidemiological, clinical and population-level data.



World Health Assembly

Member States request WHO to develop a global AMR surveillance system

<http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/>


Objectives and Development of GLASS

Objective: Foster national AMR surveillance systems through harmonized global standards to:

- Monitor AMR trends,
- Detect emerging resistance,
- Inform the estimation of AMR burden.

Development

- Collaboration: WHO Collaborating Centres; International networks; partners,
- Consultation with Member States: e.g. Stockholm, Dec 2014; April 2017; October 2020.



Initial focus: Bacterial infections in humans but the principle may also apply to other pathogens, and in one health (i.e. including animal infections, environmental contamination, etc)




Data Collected with GLASS

- **Status of national AMR surveillance system**
 - Indicators collected: overall coordination, surveillance system structure, and quality control.
- **AMR data**
 - Specimens from patients suspected to have infections,
 - Priority specimens: blood, urine, stool, cervical and urethral specimens, cerebrospinal fluid (CSF); respiratory samples; and rectal and pharyngeal swabs
 - Population data:
 - ✓ overall number of patients tested per specific specimen.
 - ✓ age, gender, and infection origin (hospital versus community).
- **GLASS AMR Pathogen indicators**
 - 13 target pathogens
 - Rationale: Listed pathogens are commonly associated with community and hospital infections; pathogens account for emerging AMR for which there are few treatment options; Common indicators used in foodborne AMR surveillance include *E. coli* and *Salmonella* spp.



Stepwise Enrolment in GLASS



GLASS Technical Support to Countries



- Manuals
- IT tools
- Help desk
- Webinars
- Country missions
- Training workshops
- EQA and procurement

Sustainable Development Goal AMR Indicator



Goal 3: Ensure healthy lives and promote well-being for all at all ages


TARGET 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks

INDICATOR 3.d.2: Proportion of bloodstream infections among patients due to

- methicillin-resistant *Staphylococcus aureus* (MRSA)
- *Escherichia coli* resistant to 3rd generation cephalosporins


Further Development

- Monitoring of antimicrobial consumption data,
- AMR surveillance in the food chain and environment 2017-2018,
- Special project on AMR for gonorrhoea (Enhanced GASP or EGASP),
- AMR surveillance in invasive fungal infection,
- Special studies to assess burden of AMR disease.



WHO Global Report on Antimicrobial Consumption

- Information on volume of sales of antimicrobial medicines
 - Proxy for consumption or use in the population,
 - Map below and report on the right presents 2015 data on consumption of antibiotics from 65 countries and areas.




One Health AMR Surveillance

The Tricycle Project - WHO Integrated Global Survey on Extended Spectrum Beta-Lactamase (ESBL) *E.coli*

- WHO has established in Member States an Integrated Surveillance System to monitor ESBL producing *E. coli* in humans, the food chain and the environment (3 compartments).
- The Project uses a simple and standardized methodology to monitor ESBL producing *E. coli* strains, permits comparison among countries regarding the presence of ESBLs in the 3 compartments, and allows the detection of the effect of interventions.
- The protocol is being implemented in four WHO Regions, AFRO included.



Levels of AMR Surveillance and Consumption Data for Policy & Decision Making in Health Systems




Data limitations!



- Limited representativeness
 - Lack of sampling strategy,
 - Few surveillance sites per country,
 - Small sample size.
- Limited access to lab tests
 - Limited lab capacity,
 - Patients need to pay out of pocket for the tests.
- Limited completeness of data.
- Most data are from hospitals.
- However, the data limitations should not impede surveillance, but rather be used to improve it and make it more robust and reliable

Key Milestones



- Countries have enrolled and are contributing data to GLASS
- More and more countries are working towards achieving a status that will enable them to **report data in a more complete and systematic manner**
- GLASS has enabled WHO to establish and monitor the **functionality of national surveillance system for AMR** and Antimicrobial Consumption
- Data contributed to GLASS **is available online**
- **Steps** for establishing National surveillance system **have been clearly outlined**
- Countries of the AFRO region are implementing the tricycle project, an Integrated Global Surveillance on ESBL producing *E.coli strains*

References

National antimicrobial resistance surveillance systems and participation in the Global Antimicrobial Resistance Surveillance System (GLASS): A guide to planning, implementation, and monitoring and evaluation. <http://apps.who.int/iris/bitstream/10665/251554/1/WHO-DGO-AMR2016.4-eng.pdf?ua=1>

Sirijatuphat R, Pongsuttiyakorn S, Supapueng O et al . Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteriuria. *Journal of Global Antimicrobial Resistance* 2020; 20:60-67

WHO. Global Antimicrobial resistance and use surveillance system (GLASS) report; Early Implementation 2020. <https://apps.who.int/iris/bitstream/handle/10665/332081/9789240005587-eng.pdf>

WHO. Global report on surveillance of antibiotic consumption, 2016-2018, early Implementation

ReACT News and Opinions 2020. 4 Key reflections on the recently launched WHO GLASS report <https://www.reactgroup.org/news-and-views/news-and-opinions/year-2020/4-key-reflections-on-the-recently-launched-who-glass-report/>

WHO. Antimicrobial resistance surveillance. https://www.who.int/medicines/areas/rational_use/AMR_Surveillance